GW Henssler & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $439K | Buy |
1,745
+99
| +6% | +$21.3K | 0.02% | 151 |
|
|
2026
Q1 | $358K | Buy |
1,646
+40
| +2% | +$8.87K | 0.02% | 157 |
|
|
2025
Q4 | $367K | Hold |
1,606
| – | – | 0.02% | 152 |
|
|
2025
Q3 | $372K | Sell |
1,606
-1,263
| -44% | -$257K | 0.02% | 145 |
|
|
2025
Q2 | $533K | Sell |
2,869
-179
| -6% | -$33.3K | 0.03% | 127 |
|
|
2025
Q1 | $639K | Buy |
3,048
+1,814
| +147% | +$353K | 0.04% | 112 |
|
|
2024
Q4 | $244K | Sell |
1,234
-61
| -5% | -$11.2K | 0.01% | 142 |
|
|
2024
Q3 | $256K | Sell |
1,295
-796
| -38% | -$149K | 0.01% | 141 |
|
|
2024
Q2 | $359K | Sell |
2,091
-162,032
| -99% | -$26.8M | 0.02% | 113 |
|
|
2024
Q1 | $29.9M | Sell |
164,123
-2,696
| -2% | -$465K | 1.76% | 17 |
|
|
2023
Q4 | $25.9M | Sell |
166,819
-2,391
| -1% | -$349K | 1.71% | 15 |
|
|
2023
Q3 | $25.2M | Sell |
169,210
-1,982
| -1% | -$291K | 1.72% | 16 |
|
|
2023
Q2 | $23.1M | Sell |
171,192
-708
| -0.4% | -$104K | 1.51% | 25 |
|
|
2023
Q1 | $27.4M | Sell |
171,900
-2,566
| -1% | -$392K | 1.82% | 10 |
|
|
2022
Q4 | $28.2M | Sell |
174,466
-983
| -0.6% | -$151K | 1.98% | 10 |
|
|
2022
Q3 | $23.5M | Buy |
175,449
+668
| +0.4% | +$95.9K | 1.76% | 16 |
|
|
2022
Q2 | $26.8M | Sell |
174,781
-1,170
| -0.7% | -$179K | 1.99% | 11 |
|
|
2022
Q1 | $28.5M | Buy |
175,951
+837
| +0.5% | +$122K | 1.73% | 14 |
|
|
2021
Q4 | $23.7M | Buy |
175,114
+855
| +0.5% | +$101K | 1.51% | 17 |
|
|
2021
Q3 | $18.8M | Buy |
174,259
+1,931
| +1% | +$221K | 1.3% | 30 |
|
|
2021
Q2 | $19.4M | Buy |
172,328
+2,738
| +2% | +$308K | 1.28% | 29 |
|
|
2021
Q1 | $18.4M | Buy |
169,590
+6,505
| +4% | +$696K | 1.31% | 32 |
|
|
2020
Q4 | $17.5M | Sell |
163,085
-1,424
| -0.9% | -$137K | 1.34% | 28 |
|
|
2020
Q3 | $14.4M | Buy |
164,509
+3,468
| +2% | +$327K | 1.22% | 34 |
|
|
2020
Q2 | $15.8M | Buy |
161,041
+15,145
| +10% | +$1.33M | 1.39% | 33 |
|
|
2020
Q1 | $11.1M | Buy |
+145,896
| New | +$12.4M | 1.13% | 45 |
|
|
2015
Q2 | – | Sell |
-3,495
| Closed | -$205K | – | 165 |
|
|
2015
Q1 | $205K | Hold |
3,495
| – | – | 0.02% | 163 |
|
|
2014
Q4 | $229K | Sell |
3,495
-123
| -3% | -$7.75K | 0.03% | 146 |
|
|
2014
Q3 | $209K | Sell |
3,618
-333
| -8% | -$18.5K | 0.03% | 135 |
|
|
2014
Q2 | $223K | Sell |
3,951
-1,845
| -32% | -$96.8K | 0.03% | 131 |
|
|
2014
Q1 | $298K | Buy |
5,796
+77
| +1% | +$3.89K | 0.04% | 134 |
|
|
2013
Q4 | $302K | Buy |
5,719
+38
| +0.7% | +$1.87K | 0.04% | 130 |
|
|
2013
Q3 | $254K | Sell |
5,681
-439
| -7% | -$19.5K | 0.03% | 130 |
|
|
2013
Q2 | $253K | Buy |
+6,120
| New | +$268K | 0.03% | 128 |
|
Other funds holding ABBV
GW Henssler & Associates's ABBV Position: Q2 2026 in Review
GW Henssler & Associates increased its AbbVie (ABBV) stake by 6% in Q2 2026, buying an estimated $21.3K and bringing the position to 1,745 shares worth $439K. The position accounts for 0.02% of the portfolio, ranked #151.
GW Henssler & Associates first reported a position in ABBV in Q2 2013 and has held it in 34 quarters since. The position peaked at $29.9M in Q1 2024. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- GW Henssler & Associates held 1,745 shares of AbbVie worth $439K as of Q2 2026.
- GW Henssler & Associates bought 99 AbbVie shares in Q2 2026, an estimated $21.3K.
- AbbVie made up 0.02% of GW Henssler & Associates's portfolio in Q2 2026, its #151 holding.
- GW Henssler & Associates first reported a position in AbbVie in Q2 2013 and has held it in 34 quarters since.
- GW Henssler & Associates's AbbVie position peaked at $29.9M in Q1 2024.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on GW Henssler & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.